Search

Your search keyword '"Qiu, Yuqin"' showing total 29 results
Start Over Author "Qiu, Yuqin" Search Limiters Full Text
29 results on '"Qiu, Yuqin"'

1. A Learning-Based Approach to Approximate Coded Computation

Author

Agrawal, Navneet, Qiu, Yuqin, Frey, Matthias, Bjelakovic, Igor, Maghsudi, Setareh, Stanczak, Slawomir, and Zhu, Jingge

Subjects
Computer Science - Information Theory, Computer Science - Machine Learning
Abstract

Lagrange coded computation (LCC) is essential to solving problems about matrix polynomials in a coded distributed fashion; nevertheless, it can only solve the problems that are representable as matrix polynomials. In this paper, we propose AICC, an AI-aided learning approach that is inspired by LCC but also uses deep neural networks (DNNs). It is appropriate for coded computation of more general functions. Numerical simulations demonstrate the suitability of the proposed approach for the coded computation of different matrix functions that are often utilized in digital signal processing., Comment: Submitted to IEEE Information Theory Workshop (ITW) 2022

Published
2022

3. Preparation and In Vitro/In Vivo Characterization of Mixed-Micelles-Loaded Dissolving Microneedles for Sustained Release of Indomethacin.

Author

Wang, Baojie, Liao, Langkun, Liang, Huihui, Chen, Jiaxin, and Qiu, Yuqin

Subjects
TRANSDERMAL medication, ADJUVANT arthritis, RHEUMATOID arthritis, PLASMA stability, ANTI-inflammatory agents
Abstract

Background/Objectives: Indomethacin (IDM) is commonly used to treat chronic inflammatory diseases such as rheumatoid arthritis and osteoarthritis. However, long-term oral IDM treatment can harm the gastrointestinal tract. This study presents a design for encapsulating IDM within mixed micelles (MMs)-loaded dissolving microneedles (DMNs) to improve and sustain transdermal drug delivery. Methods: Indomethacin-loaded mixed micelles (IDM-MMs) were prepared from Soluplus® and Poloxamer F127 by means of a thin-film hydration method. The MMs-loaded DMNs were fabricated using a two-step molding method and evaluated for storage stability, insertion ability, in vitro release, in vitro transdermal penetration, and in vivo PK/PD studies. Results: The obtained MMs were stable at 4 °C and 30 °C for 60 days. The in vitro IDM transdermal penetration was remarkably improved by the MMs-loaded DMNs compared to a commercial patch. A pharmacokinetic study demonstrated that the MMs-loaded DMNs had a relative bioavailability of 4.1 in comparison with the commercial patch. Furthermore, the MMs-loaded DMNs showed a significantly shorter lag time than the commercial patch, as well as a more stable plasma concentration than the DMNs without MMs. The therapeutic efficacy of the IDM DMNs was examined in Complete Freund's Adjuvant-induced arthritis mice. The IDM DMN treatment effectively reduced arthritis severity, resulting in decreased paw swelling, arthritis index, spleen hyperplasia, and serum IL-1β and TNF-α levels. Conclusions: Our findings demonstrated that the novel MMs-loaded DMNs were an effective strategy for sustained IDM release, providing an alternate route of anti-inflammatory drug delivery. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Ultrasonication-Induced Preparation of High-Mechanical-Strength Microneedles Using Stable Silk Fibroin.

Author

Liang, Huihui, Chen, Jiaxin, Qiu, Guirong, Guo, Bohong, and Qiu, Yuqin

Subjects
TRANSDERMAL medication, SILK fibroin, X-ray diffraction, SONICATION, MECHANICAL heat treatment
Abstract

Silk fibroin (SF) is an ideal material for microneedle (MN) preparation. However, long extraction and short storage durations limit its application. Furthermore, MNs prepared from SF alone are easy to break during skin insertion. In this study, a regenerated SF solution was autoclaved and freeze-dried to produce a stable and water-soluble SF sponge. The freeze-dried SF (FD-SF) solution was ultrasonically treated before being used in the fabrication of MNs. The ultrasonically modified SFMNs (US-SFMNs) were evaluated in comparison to FD-SFMNs made from FD-SF and conventional SFMNs made from regenerated SF. The results indicated that the FD-SF could be completely dissolved in water and remained stable even after 8 months of storage. FTIR and XRD analyses showed that SF in US-SFMNs had increased β-sheet content and crystallization compared to FD-SFMNs, by 7.3% and 8.1%, respectively. The US-SFMNs had higher mechanical strength than conventional SFMNs and FD-SFMNs, with a fracture force of 1.55 N per needle and a rat skin insertion depth of 370 μm. The US-SFMNs also demonstrated enhanced transdermal drug delivery and enzymatic degradation in vitro. In conclusion, the autoclaving and freeze drying of SF, as well as ultrasonication-induced MN preparation, provide promising SF-based microneedles for transdermal drug delivery. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Correction: TET2–STAT3–CXCL5 nexus promotes neutrophil lipid transfer to fuel lung adeno-to-squamous transition

Author

Xue, Yun, primary, Chen, Yuting, additional, Sun, Sijia, additional, Tong, Xinyuan, additional, Chen, Yujia, additional, Tang, Shijie, additional, Wang, Xue, additional, Bi, Simin, additional, Qiu, Yuqin, additional, Zhao, Qiqi, additional, Qin, Zhen, additional, Xu, Qin, additional, Ai, Yingjie, additional, Chen, Leilei, additional, Zhang, Beizhen, additional, Liu, Zhijie, additional, Ji, Minbiao, additional, Lang, Meidong, additional, Chen, Luonan, additional, Xu, Guoliang, additional, Hu, Liang, additional, Ye, Dan, additional, and Ji, Hongbin, additional

Published
2024
Full Text
View/download PDF

6. TET2–STAT3–CXCL5 nexus promotes neutrophil lipid transfer to fuel lung adeno-to-squamous transition

Author

Xue, Yun, primary, Chen, Yuting, additional, Sun, Sijia, additional, Tong, Xinyuan, additional, Chen, Yujia, additional, Tang, Shijie, additional, Wang, Xue, additional, Bi, Simin, additional, Qiu, Yuqin, additional, Zhao, Qiqi, additional, Qin, Zhen, additional, Xu, Qin, additional, Ai, Yingjie, additional, Chen, Leilei, additional, Zhang, Beizhen, additional, Liu, Zhijie, additional, Ji, Minbiao, additional, Lang, Meidong, additional, Chen, Luonan, additional, Xu, Guoliang, additional, Hu, Liang, additional, Ye, Dan, additional, and Ji, Hongbin, additional

Published
2024
Full Text
View/download PDF

24. Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report

Author

Duan,Hua, Peng,Yanmei, Cui,Huijuan, Qiu,Yuqin, Li,Qiang, Zhang,Jingyi, Shen,Wen, Sun,Chenyao, and Luo,Chufan

Subjects
OncoTargets and Therapy, respiratory tract diseases
Abstract

Hua Duan,1 Yanmei Peng,1 Huijuan Cui,2 Yuqin Qiu,1 Qiang Li,1 Jingyi Zhang,1 Wen Shen,1 Chenyao Sun,1 Chufan Luo1 1Department of China–Japan Friendship Hospital, Beijing University of Chinese Medicine, Beijing, China; 2Department of Oncology, China–Japan Friendship Hospital, Chaoyang, Beijing, China Abstract: Epidermal growth factor receptor-tyrosine kinase inhibitors have improved progression-free survival and overall survival in non-small-cell lung cancer (NSCLC) patients with sensitive mutations. However, response of uncommon mutation to epidermal growth factor receptor-tyrosine kinase inhibitors is still unclear. S768I is one of the uncommon mutations. A female patient with advanced NSCLC with a single S768I mutation achieved effectiveness from afatinib after showing no response to gefitinib. The patient had progression-free survival after taking afatinib for 6 months, and her follow-up is continuing. It suggests that afatinib may be a more effective treatment for NSCLC patients with a single S768I mutation, compared to first-generation tyrosine kinase inhibitors. Keywords: NSCLC, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), S768I, afatinib, gefitinib&nbsp

Published
2018

26. Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report

Author

Peng,Yanmei, Cui,Huijuan, Liu,Zhe, Liu,Daiwei, Liu,Fan, Song,Yazhong, Duan,Hua, Qiu,Yuqin, and Li,Qiang

Subjects
OncoTargets and Therapy
Abstract

Yanmei Peng,1 Huijuan Cui,2 Zhe Liu,3 Daiwei Liu,1 Fan Liu,1 Yazhong Song,1 Hua Duan,1 Yuqin Qiu,1 Qiang Li1 1Department of China-Japan Friendship Hospital, Beijing University of Chinese Medicine, 2Department of Oncology, China-Japan Friendship Hospital, Chaoyang, 3Department of Oncology, Beijing Chest Hospital, Tongzhou, Beijing, People’s Republic of China Abstract: Lung adenocarcinoma is the most common pathological pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. In the present clinical practice, antagonists of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF)-directed therapies are widely used. In the former category, the agent erlotinib (tyrosine kinase inhibitor) has shown obvious advantages over cytotoxic therapy. Anti-VEGF therapy bevacizumab used for lung adenocarcinoma was recommended in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) as first-line therapy. Similarly, apatinib is speculated to response by selectively inhibiting the vascular endothelial growth factor receptor-2. The patient with unknown EGFR status benefited 5-month progressive free survival (PFS) from erlotinib, and then another 5.1-month PFS with combined treatment of apatinib, which suggested a new option for lung adenocarcinoma. However, when dabigatran was used to cancer-related venous thromboembolism during apatinib therapy, extensive subcutaneous bleeding occurred, warning us against the risks of bleeding. Besides, hypertension and anorexia were observed, causing dosage adjustment. Keywords: NSCLC, epidermal growth factor receptor, vascular endothelial growth factor, venous thromboembolism, dabigatran

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results